Skip to main content

Table 1 Clinical characteristics of the study population.

From: A comparative study of varying doses of enoxaparin for thromboprophylaxis in critically ill patients: a double-blinded, randomised controlled trial

Enoxaparin dose 40 mg QD
(N = 20)
30 mg BID
(N = 20)
40 mg BID
(N = 19)
1 mg/kg QD
(N = 19)
P value
Sex (male:female) 12:8 14:6 8:11 9:10 0.31
Age (years) 59.9 ± 10.8 65.8 ± 14.7 65.6 ± 15.8 63.5 ± 13.8 0.44
Weight (kg) 69.6 ± 12.2 68.5 ± 10.9 67.8 ± 11.8 74.8 ± 9.4 0.71
SAPS II 40.2 ± 11.8 41.6 ± 10.4 44.9 ± 14.8 45.2 ± 16.6 0.18
APACHE II 20.7 ± 6.5 21.5 ± 6.0 22.6 ± 6.1 23.7 ± 7.4 0.80
SOFA 4.7 ± 1.7 4.6 ± 1.8 4.7 ± 1.4 4.4 ± 1.5 0.73
Creatinine clearance (ml/min) 83 ± 14.2 83 ± 12.8 80 ± 18.0 77.8 ± 18.4 0.33
Medical:surgical 17:3 19:1 16:3 17:2 0.73
  1. Plus-minus values are means ± standard deviation (SD). QD, once daily: BID, twice daily; N, number; SAPS II, Simplified Acute Physiology Score II: APACHE II, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment score.